Aeon Biopharma (AEON) said Friday it received a notice from NYSE American stating it is not in compliance with the stockholders' equity requirement, which requires at least $2 million in equity.
The company reported a stockholders' deficit of $32.1 million as of Sept. 30 and has incurred losses from continued operations in two of its most recent fiscal years.
Aeon said it has until March 5 to submit a plan to regain compliance and intends to do so
Shares of Aeon Biopharma were down more than 7% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。